Your browser doesn't support javascript.
loading
De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.
Cioni, Michela; Nocera, Arcangelo; Innocente, Annalisa; Tagliamacco, Augusto; Trivelli, Antonella; Basso, Sabrina; Quartuccio, Giuseppe; Fontana, Iris; Magnasco, Alberto; Drago, Francesca; Gurrado, Antonella; Guido, Ilaria; Compagno, Francesca; Garibotto, Giacomo; Klersy, Catherine; Verrina, Enrico; Ghiggeri, Gian Marco; Cardillo, Massimo; Comoli, Patrizia; Ginevri, Fabrizio.
Afiliação
  • Cioni M; Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
  • Nocera A; Clinical Nephrology Unit and Transplant Immunology Research Laboratory, Department of Internal Medicine, University of Genova and IRCCS San Martino University Hospital IST, Genova, Italy.
  • Innocente A; Transplantation Immunology, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
  • Tagliamacco A; Clinical Nephrology Unit and Transplant Immunology Research Laboratory, Department of Internal Medicine, University of Genova and IRCCS San Martino University Hospital IST, Genova, Italy.
  • Trivelli A; Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
  • Basso S; Pediatric Hematology/Oncology and Cell Factory, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Quartuccio G; Pediatric Hematology/Oncology and Cell Factory, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Fontana I; Vascular and Endovascular Unit and Kidney Transplant Surgery Unit, University of Genova, IRCCS San Martino University Hospital IST, Genova, Italy.
  • Magnasco A; Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
  • Drago F; Transplantation Immunology, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
  • Gurrado A; Pediatric Hematology/Oncology and Cell Factory, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Guido I; Pediatric Hematology/Oncology and Cell Factory, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Compagno F; Pediatric Hematology/Oncology and Cell Factory, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Garibotto G; Clinical Nephrology Unit and Transplant Immunology Research Laboratory, Department of Internal Medicine, University of Genova and IRCCS San Martino University Hospital IST, Genova, Italy.
  • Klersy C; Biometry and Statistics Service, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Verrina E; Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
  • Ghiggeri GM; Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
  • Cardillo M; Transplantation Immunology, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
  • Comoli P; Pediatric Hematology/Oncology and Cell Factory, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Ginevri F; Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
J Immunol Res ; 2017: 1747030, 2017.
Article em En | MEDLINE | ID: mdl-28367453
De novo posttransplant donor-specific HLA-antibody (dnDSA) detection is now recognized as a tool to identify patients at risk for antibody-mediated rejection (AMR) and graft loss. It is still unclear whether the time interval from transplant to DSA occurrence influences graft damage. Utilizing sera collected longitudinally, we evaluated 114 consecutive primary pediatric kidney recipients grafted between 2002 and 2013 for dnDSA occurrence by Luminex platform. dnDSAs occurred in 39 patients at a median time of 24.6 months. In 15 patients, dnDSAs developed within 1 year (early-onset group), while the other 24 seroconverted after the first posttransplant year (late-onset group). The two groups were comparable when considering patient- and transplant-related factors, as well as DSA biological properties, including C1q and C3d complement-binding ability. Only recipient age at transplant significantly differed in the two cohorts, with younger patients showing earlier dnDSA development. Late AMR was diagnosed in 47% of the early group and in 58% of the late group. Graft loss occurred in 3/15 (20%) and 4/24 (17%) patients in early- and late-onset groups, respectively (p = ns). In our pediatric kidney recipients, dnDSAs predict AMR and graft loss irrespective of the time elapsed between transplantation and antibody occurrence.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Rejeição de Enxerto / Antígenos HLA / Isoanticorpos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Immunol Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Rejeição de Enxerto / Antígenos HLA / Isoanticorpos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Immunol Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália